Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis: The aim of this study was to describe the long-term trends in cancer mortality rates in people with type 2 diabetes based on subgroups defined by sociodemographic characteristics and risk factors. Methods: We defined a cohort of individuals aged ≥35 years who had newly diagnosed type 2 diabetes in the Clinical Practice Research Datalink between 1 January 1998 and 30 November 2018. We assessed trends in all-cause, all-cancer and cancer-specific mortality rates by age, gender, ethnicity, socioeconomic status, obesity and smoking status. We used Poisson regression to calculate age- and calendar year-specific mortality rates and Joinpoint regression to assess trends for each outcome. We estimated standardised mortality ratios comparing mortality rates in people with type 2 diabetes with those in the general population. Results: Among 137,804 individuals, during a median follow-up of 8.4 years, all-cause mortality rates decreased at all ages between 1998 and 2018; cancer mortality rates also decreased for 55- and 65-year-olds but increased for 75- and 85-year-olds, with average annual percentage changes (AAPCs) of –1.4% (95% CI –1.5, –1.3), –0.2% (–0.3, –0.1), 1.2% (0.8, 1.6) and 1.6% (1.5, 1.7), respectively. Higher AAPCs were observed in women than men (1.5% vs 0.5%), in the least deprived than the most deprived (1.5% vs 1.0%) and in people with morbid obesity than those with normal body weight (5.8% vs 0.7%), although all these stratified subgroups showed upward trends in cancer mortality rates. Increasing cancer mortality rates were also observed in people of White ethnicity and former/current smokers, but downward trends were observed in other ethnic groups and non-smokers. These results have led to persistent inequalities by gender and deprivation but widening disparities by smoking status. Constant upward trends in mortality rates were also observed for pancreatic, liver and lung cancer at all ages, colorectal cancer at most ages, breast cancer at younger ages, and prostate and endometrial cancer at older ages. Compared with the general population, people with type 2 diabetes had a more than 1.5-fold increased risk of colorectal, pancreatic, liver and endometrial cancer mortality during the whole study period. Conclusions/interpretation: In contrast to the declines in all-cause mortality rates at all ages, the cancer burden has increased in older people with type 2 diabetes, especially for colorectal, pancreatic, liver and endometrial cancer. Tailored cancer prevention and early detection strategies are needed to address persistent inequalities in the older population, the most deprived and smokers. Graphical abstract:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benchimol, E. I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., Sørensen, H. T., von Elm, E., Langan, S. M., & RECORD Working Committee (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001885 · Cited by 5,749 · cited 1×
“19_120Mn), and the RECORD guidelines (see checklist in the electronic supplementary material [ESM]) [13].”
BackgroundDiabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 1×
“The CPRD routinely collects de-identified patient data, which are generally representative of the national population in terms of age, sex and ethnicity [14].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749 · cited 2×
“Previous studies have reported declining rates in the last two decades of major cardiovascular complications and mortality in people with diabetes in some high-income countries [3, 4], with parallel greater contributions of other diseases, such as cancer, as the underlying causes of death [5].”
BackgroundResultHow can I deal with missing data in my study?
Bennett, D. A. (2001) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1467-842x.2001.tb00294.x · Cited by 1,656 · cited 1×
“missing data on each factor were not included in the corresponding subgroup analysis but our results are unlikely to be strongly biased, given the small number of missing data (<10%) [30].”
BackgroundType 2 diabetes in adolescents and young adults
Lascar, N., Brown, J., Pattison, H., Barnett, A. H., Bailey, C. J., & Bellary, S. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30186-9 · Cited by 824 · cited 1×
“At the same time, the more proactive identification of cases of type 2 diabetes earlier in the trajectory of the disease, alongside changes in diagnostic criteria, the increasing incidence of early-onset type 2 diabetes [22] and the availability of newer glucose-lowering treatments with robust cardioprotective effects…”
BackgroundGregg, E. W., Cheng, Y. J., Srinivasan, M., Lin, J., Geiss, L. S., Albright, A. L., & Imperatore, G. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30314-3 · Cited by 480 · cited 5×
“While declining trends in the rates of all-cause mortality among people with diabetes, mainly because of reduced vascular mortality rates [27, 28, 31, 32], have been consistently reported in the literature [4, 5, 27, 28, 31–38], the evidence is less clear for cancer, making a coherent understanding of the cancer burde…”
ResultInfluentialPearson-Stuttard, J., Bennett, J., Cheng, Y. J., Vamos, E. P., Cross, A. J., Ezzati, M., & Gregg, E. W. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30431-9 · Cited by 335
Mortality Trends Among People With Type 1 and Type 2 Diabetes in Australia: 1997–2010
Harding, J. L., Shaw, J. E., Peeters, A., Guiver, T., Davidson, S., & Magliano, D. J. (2014) · Diabetes Care · doi:10.2337/dc14-0096 · Cited by 158
Cited by
Wang, L., Xu, R., Kaelber, D. C., & Berger, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21305 · Cited by 304
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
“For domains 3, 4, 5, the present meta-analysis's primary endpoint, that is, the incidence of malignancies, was considered as the outcome of interest.”
Tuning insulin receptor signaling using de novo-designed agonists
Wang, X., Cardoso, S., Cai, K., Venkatesh, P., Hung, A., Ng, M., Hall, C., Coventry, B., Lee, D. S., Chowhan, R., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.09.020 · Cited by 24
Metadata
- Authors
- Ling, S., Zaccardi, F., Issa, E., Davies, M. J., Khunti, K., & Brown, K.
- Venue
- Diabetologia
- Published
- 2023-01-24
- Volume
- 66
- Issue
- 4
- Pages
- 657-673
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W4317781515
- Cited by
- 52
- References
- 12
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England. https://app.cochat.ai/papers/10.1007/s00125-022-05854-8
- The paper
- Ling, S., Zaccardi, F., Issa, E., Davies, M. J., Khunti, K., & Brown, K. (2023). Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England. Diabetologia. https://doi.org/10.1007/s00125-022-05854-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.